Navigation Links
Savient Pharmaceuticals to Hold Fourth Quarter and Year-End 2008 Results Conference Call on Thursday, February 26, 2009
Date:2/17/2009

EAST BRUNSWICK, N.J., Feb. 17 /PRNewswire-FirstCall/ --Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced today that the company will release financial results for the fourth quarter and year-end 2008 following the close of the market on Wednesday, February 25, 2009.

Paul Hamelin, President and David Gionco, Vice President and Chief Financial Officer, will host an investment community conference call beginning at 10:00 a.m. Eastern Time on February 26, 2009 to discuss these results and to answer questions.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of Savient Pharmaceuticals' web site at http://www.savient.com. To listen to the live call, please go to the web site fifteen minutes prior to its start to register, download, and install the necessary audio software.

A replay will be available on the web site. A telephone replay will be available from 12:00 p.m. Eastern Time on February 26, 2009 through 11:59 p.m. Eastern Time on March 13, 2009 by dialing (888) 203-1112 (domestic) or (719) 457-0820 (international) and entering conference ID number 5547271.

ABOUT SAVIENT PHARMACEUTICALS, INC.

Savient Pharmaceuticals, Inc. is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The company's product development candidate, KRYSTEXXA(TM) (pegloticase) for treatment-failure gout, has reported positive Phase 1, 2 and 3 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007; and the Phase 3 clinical studies were completed in October 2007, the BLA was filed with the FDA in Octo
'/>"/>

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Savient Pharmaceuticals to Hold Third Quarter 2008 Financial Results Conference Call on Thursday, November 6, 2008
2. Savients Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference
3. Savient Submits Biologics License Application (BLA) for pegloticase
4. Savient Pharmaceuticals Reports Third Quarter 2008 Financial Results
5. Savient Pharmaceuticals to Present at the Lazard Capital Markets 5th Annual Healthcare Conference on November 18th
6. Savient Announces Appointment of David Gionco as Chief Financial Officer
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... DOVER, Delaware , August 3, 2015 ... engaged in the commercialization of its Bio-electrical Signal Therapy ... the noninvasive treatment of hard to heal chronic wounds, ... distribution agreement with Chemipal, an Israeli distributor specializing in ... BST device. Chemipal is a 70 years ...
(Date:8/3/2015)... - RepliCel Life Sciences Inc. (TSX.V: RP) (OTCQB: REPCF), a ... autologous cell therapies, announced today that RepliCel,s CEO, David ... in Minneapolis, Minnesota on August 5 ... highlight RepliCel,s 18-month milestones including CE Mark for its RCI-02 ... clinical data from both RCT-01 (tendon) and RCS-01 (skin) clinical ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... ... offering competitive market analysis and premium industry insights on the global resorcinol industry. ... on a collective study of vivid market scenarios and analysis of primary and ...
(Date:7/30/2015)... ... July 31, 2015 , ... Ralco is honored to announce ... Lyon County Fair to be held August 5-9 in Marshall. The Ralco Enrichment Center ... come from and how agriculture impacts their daily lives. This unique exhibit also features ...
Breaking Biology Technology:E-QURE Corp Signs Second Distribution Agreement in Israel 2E-QURE Corp Signs Second Distribution Agreement in Israel 3RepliCel Presenting at InvestMNT Investor Conference in Minneapolis 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2
... ... is set to revolutionize the healthcare industry. As our knowledge of genetics and molecular ... , ... May 18, 2010 -- The era of Personalized Medicine is set to revolutionize the ...
... ... Consulting’s CloudCraze product to build an enterprise-class, cross-channel B-to-B webstore for the company’s ... platform and utilizing EDL’s CloudCraze eCommerce product, the new site will allow Gilson ... , ...
... , , , ... , , ... FDA for Home/Self use and is,consequently available to all patients with home hemodialysis in the ... already improved in-clinic patient,safety. Optimizing safety conditions for home hemodialysis users is a core,ambition for ...
Cached Biology Technology:Arrowhead Releases New Report Assessing State of Personalized Medicine Market 2Arrowhead Releases New Report Assessing State of Personalized Medicine Market 3Gilson, Inc. Selects EDL Consulting's CloudCraze For Cross-Channel Webstore Expansion in Europe 2Gilson, Inc. Selects EDL Consulting's CloudCraze For Cross-Channel Webstore Expansion in Europe 3Redsense Medical Receives FDA Clearance for the Redsense Safety Device for Home/Self use During Home Hemodialysis 2
(Date:7/8/2015)... 8, 2015 Summary Pancreatic cancer is ... most fatal, with a mortality rate of 10.9 deaths ... pancreatic cancer patients has highlighted a significant need for ... being met by the current market. A highly ... with varying molecule types and mechanisms of action, which ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... Laboratory, ST Microelectronics, the University of Edinburgh, and TU ... of the Megaframe Imager - an ultrafast camera capable ... million frames Since the introduction of solid-state optical ... trend has been towards increasing the resolution (i.e. number ...
... The well-reported arsenic contamination of drinking water in ... population in history" by the World Health Organization and ... diseases has now been shown to have an ... An international team of economists is the first ...
... November 29, 2010 - For Immediate Release A ... a previously unknown regulatory mechanism in the body,s response to ... a long-held dogma in the field of immunology and have ... administered to the origin of autoimmunity. The results of ...
Cached Biology News:Arsenic-polluted water toxic to Bangladesh economy 2Arsenic-polluted water toxic to Bangladesh economy 3Arsenic-polluted water toxic to Bangladesh economy 4Scripps Research scientists redefine the role of plasma cells in the immune system 2Scripps Research scientists redefine the role of plasma cells in the immune system 3Scripps Research scientists redefine the role of plasma cells in the immune system 4
... Thermocycler combines top performance with exquisite design. ... speed and unparalleled temperature uniformity. The instrument ... in a spreadsheet or alternatively in a ... opens on the push of a button ...
Preparation TW--Compatibility: no end cap seals -Hybridization Tube for Hybrigene -Comp Dim: 240 80 mm -Material: borosilicate glass -Mfr Desig: Techne FHB-15...
... is Tecans state-of-the-art software for all your ... scheduling in a single, scalable software package. ... consistent, simplifying the control of all Freedom ... Freedom EVO 100 with one liquid handling ...
... Kit provides all the reagents required ... fraction. The isolation procedure involves tissue ... and differential centrifugation followed by an ... contains an antibody specific for synaptophysin, ...
Biology Products: